www.isoray.com. Pioneering Internal Radiation Therapy with Cesium 131. v092911. Forward Looking Statements.
Pioneering Internal Radiation Therapy with Cesium131
This presentation contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology.
These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risks outlined under “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on September 28, 2011. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Source: Oak Ridge Associated Universities
LDR Brachytherapy for Prostate Cancer
Source: Mayo Foundation
SAV I Catheter for Breast Cancer
Source: Cianna Medical
Source: Frost Sullivan Report 2004
Autoradiograph of an IsoRay seed (4.5 mm)
The above information is considered standard dosing information. Such information is governed by the FDA and is required to accompany any product that is distributed to a customer and intended for use. Acquisition of this information can be obtained from the company that manufactures each listed product.
There were an estimated 1,479,3501 new cases of cancer diagnosed in the U.S. in 2010:
(2000 cases x $119 x 25 seeds)
(4000 cases x $119 x 40 seeds)
(13,000 cases x $72 asp x 85 seeds)
(200 cases x $119 x 15 seeds)
(2000 cases x $119 x 30 seeds)
(10,000 cases x $199 x 40 seeds)
*assuming the current reimbursement rates (which are subject to annual review and adjustment), remain constant